VistaGen FY26 net loss widens to $69.7 million; R&D expense rises to $55 million

Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc.

VTGN

0.00
  • VistaGen posted a net loss of USD 69.7 million, widening from USD 51.4 million a year earlier; net loss per share was USD 1.83.
  • Research and development expense climbed to USD 55 million from USD 39.4 million; general and administrative expense rose to USD 18.4 million from USD 17.1 million.
  • Cash, cash equivalents, and marketable securities totaled USD 45.4 million at March 31, 2026; runway expected to extend into 2027.
  • Completed randomized portion of PALISADE-4 Phase 3 fasedienol trial; topline results expected in June 2026.
  • CEO Shawn Singh said PALISADE-4, if successful, could support a potential fasedienol NDA for acute treatment of social anxiety disorder.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606151630BIZWIRE_USPR_____20260615_BW159406) on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.